Solasia Pharma K.K. (FRA:9SO)

Germany · Delayed Price · Currency is EUR

0.1290

+0.0020 (1.57%)

Last updated: Oct 23, 2026, 9:43 PM CEST

Market Cap	41.98M -17.3%
Revenue (ttm)	2.09M +32.4%
Net Income	-4.85M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369
Open	0.1280
Previous Close	0.1270
Day's Range	0.1280 - 0.1290
52-Week Range	0.0935 - 0.2000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Solasia Pharma K.K.

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherapy-induced peripheral neuropathy; and SP-05, which is in a preclinical t... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2006

Employees 22

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 9SO

Financial Performance

In 2025, Solasia Pharma K.K.'s revenue was 429.00 million, an increase of 35.76% compared to the previous year's 316.00 million. Losses were -876.00 million, -54.87% less than in 2024.

Financial numbers in JPY Financial Statements